News and events

June 5, 2020

InSysBio presents IRT Navigator 3 which is an application software providing intuitive interface to work with the Immune Response Template Database in accordance with the user’s needs. It supplies the navigation within the schemes and components and efficient development of QSP models based on IRT Database.

InSysBio to announce the launch of QSP model of COVID-19

June 2, 2020

The new open source project to be developed and updated Online

InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, announces the launch of its fundamentally new project in response to the ongoing global threat, the open source QSP model of COVID-19. In accordance with its mission, which is to assist pharmaceutical industry to speed up the delivery of the cure to patients, InSysBio team could not stay aside. Thus, the aim of the new project is to develop QSP model of COVID-19 describing virus and host cell life cycles, innate and adoptive immune response and possible therapeutic treatments.

InSysBio to take part in AACR Virtual Annual Meeting II

May 15, 2020

InSysBio announces its participation in AACR Virtual Annual Meeting II June 22-24, American Association for Cancer Research Annual Meeting which is held virtually this year due to COVID-19 spread. Today InSysBio team's abstracts were published on AACR website

InSysBio innovates its Immune Response Template Database

April 15, 2020

IRT version 3.1.0 acquires some principal upgrades

(Moscow – 15.04.2020) InSysBio is one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling has published the new version of IRT database, one of its core products.

InSysBio to announce the release of its new database Cytocon DB 1.1

March 31, 2020

Cytocon DB 1.1 facilitates access of QSP modelers to baseline in vivo data in public domain

(Moscow - 31.03.2020) InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) platform development and provision, has released its new Cytocon DB 1.1. The name of the database derives from Cell and cYTOkine CONcentrations.

InSysBio to share the news from QSPC2020 management

March 10, 2020

Today we have received the concerning news from QSPC2020 organizers about the cancellation of the conference in response to COVID-19 outbreak continuation. Quantitative Systems Pharmacology Conference 2020 was planned to be held in April 22-24, 2020 Leiden, The Netherlands. InSysBio team was prepared to present 10 posters

13th InSysBio Annual Internal Scientific Meeting

March 3, 2020

26-28 February 2020 InSysBio QSP-company held its 13th Annual Internal Scientific Meeting. InSysBio team presented the results of 2019 year professional progress. Every member demonstrated their personal achievements and shared the plans for the future development. Oleg Demin, InSysBio CEO and founder, summarized all the company’s advancement of the year 2019.

InSysBio presents an enhanced version of its Immune Response Template Database

February 21, 2020

IRT Version 3.0.0 acquires a wide variety of updates and new options

(Moscow – 21.02.2020) InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) platform development and provision, moves forward to the future.

InSysBio to participate in ASCPT 2020

February 19, 2020

InSysBio announced its participation in 121st Annual meeting of American Society for Clinical Pharmacology and Therapeutics (ASCPT 2020) which is to be held on March 18-21, 2020 at Marriott Marquis Houston, TX. InSysBio welcomes visitors at the booth # 102. Oleg Demin, CEO of InSysBio, Tatiana Karelina, lead modeler in Alzheimer's Disease and Veronika Musatova, Head of IRT development team, will present the new version of IRT (Immune Response Template) and Cytocon DB (Cell and cYTOkine CONcentrations).

InSysBio QSP model for BTK inhibitors will be presented at the 61 ASH Annual Meeting

December 3, 2019

QSP model of BTK inhibitors developed by InSysBio in collaboration with BeiGene will be presented as a poster by Srikumar Sahasranaman from Beigene at 61st American Society of Hematology (ASH) Annual Meeting & Exposition. The model describes marketed BTK inhibitors (ibrutinib and acalabrutinib) and zanubrutinib, a BTK inhibitor which recently received accelerated approval from the FDA as a treatment for mantle cell lymphoma (MCL) in adult patients who have received at least one prior therapy.